NetGoodIndexSubmit a correction

Benefit Ledger · verified · Biology

OpenCRISPR-1 edits the human genome with an AI-designed Cas effector

Profluent’s language-model-designed OpenCRISPR-1 showed Cas9-like editing in human cells and base-editor compatibility, posted in 2024 and published in Nature on 30 July 2025.

30 Jul 2025Tier 3 MajorMethodology 0.1

Current score

+1.67

10 base · Major (tier 3 of 5, 10 pts)
× 0.8000 attribution · Primary causal contribution
× 0.7000 evidence · Peer review or independent validation
× 0.5000 realization · Experimentally validated
× 0.7000 durability
Event-level product before credit split: 1.96

First well-documented AI-designed CRISPR effector with human-cell editing (tier 3). High but not exclusive attribution (mining, assays). Nature paper. Realization is a research reagent. Durable sequence IP/resource.

What happened

Models trained on more than one million mined CRISPR operons generated Cas-like proteins hundreds of mutations from SpCas9. OpenCRISPR-1 was characterized for on-target activity, PAM preference, and reduced off-target editing in the authors’ assays, and released for research use. Results are cell-based, not a licensed therapy.

Model attribution

+1.67

Profluent PLM

Generated Cas-like sequences including OpenCRISPR-1.

The editor sequence was model-generated; humans mined data and ran cell assays.

Attribution 0.8000 · Credit share 85% · Profluent

Claims

  • OpenCRISPR-1 performed programmable editing in human cells and could be used as a base-editor nickase.

    outcome · supported

Sources

primary sources

Secondary domains: Medicine & Health

Revision history

  • 13 Sep 2026 · 0.00 → 1.67

    Initial adjudicated seed score under methodology 0.1.